Although no MKK1/2 or ERK1/2 inhibitors were developed for clinical use, kinase inhibitors that also inhibit Raf kinases (e.g. Sorafenib) are successful antineoplastic agents against various types of cancer.
Aínda que non se desenvolveu ningún inhibidor de MKK1/2 ou ERK1/2 para uso clínico, os inhibidores da quinase que tamén inhiben Raf quinases (por exemplo Sorafenib) son axentes antineoplásticos efectivos contra varios tipos de cancro.